Outcome after cytoreductive surgery combined with hyperthermic intrathoracic chemotherapy in patients with secondary pleural metastases

• Verfasst von: Hassan, Mohamed [VerfasserIn]
• Verfasst von: Zimmermann, Julia [VerfasserIn]
• Verfasst von: Schmid, Severin Thomas [VerfasserIn]
• Verfasst von: Passlick, Bernward [VerfasserIn]
• Verfasst von: Kovács, Julia Regina [VerfasserIn]
• Verfasst von: Hatz, Rudolf [VerfasserIn]
• Verfasst von: Winter, Hauke [VerfasserIn]
• Verfasst von: Klotz, Laura Valentina [VerfasserIn]
• Verfasst von: Eichhorn, Martin E. [VerfasserIn]
• Verfasst von: Markowiak, Till Marvin [VerfasserIn]
• Verfasst von: Müller, Karolina [VerfasserIn]
• Verfasst von: Huppertz, Gunnar [VerfasserIn]
• Verfasst von: Koller, Michael [VerfasserIn]
• Verfasst von: Hofmann, Hans-Stefan [VerfasserIn]
• Verfasst von: Ried, Michael [VerfasserIn]
• Titel: Outcome after cytoreductive surgery combined with hyperthermic intrathoracic chemotherapy in patients with secondary pleural metastases
• Verf.angabe: Mohamed Hassan, Julia Zimmermann, Severin Schmid, Bernward Passlick, Julia Kovács, Rudolf Hatz, Hauke Winter, Laura V. Klotz, Martin E. Eichhorn, Till Markowiak, Karolina Müller, Gunnar Huppertz, Michael Koller, Hans-Stefan Hofmann and Michael Ried
• E-Jahr: 2023
• Jahr: 28 November 2023
• Umfang: 9 S.
• Fussnoten: Gesehen am 27.05.2024
• Titel Quelle: Enthalten in: Frontiers in oncology
• Ort Quelle: Lausanne : Frontiers Media, 2011
• Jahr Quelle: 2023
• Band/Heft Quelle: 13(2023), Artikel-ID 1259779, Seite 1-9
• ISSN Quelle: 2234-943X
• DOI: doi:10.3389/fonc.2023.1259779
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: cytoreductive surgery2
• Sach-SW: HITOC1
• Sach-SW: hyperthermic intrathoracic chemotherapy5
• Sach-SW: non-small cell lung cancer4
• Sach-SW: pleural metastases3
• K10plus-PPN: 1889864374

Abstract

Background: The role of cytoreductive surgery combined with hyperthermic intrathoracic chemotherapy (CRS+HITOC) for patients with secondary pleural metastases has scarcely been investigated. Patients and Methods: We conducted a retrospective, multicentre study investigating the outcome of CRS+HITOC for 31 patients with pleural metastases from different primary tumours in four high-volume departments of thoracic surgery in Germany. The primary endpoint was overall survival (OS). Secondary endpoints included postoperative complications and recurrence/progression-free survival (RFS/PFS). Results: The primary tumour was non-small cell lung cancer in 12 (39%), ovarian cancer in 5 (16%), sarcoma in 3 (10%), pseudomyxoma peritonei in 3 (10%), and others in 8 (26%) patients. A macroscopic complete resection (R/1) could be achieved in 28 (90%) patients. Major postoperative complications as classified by Clavien-Dindo (III-V) were observed in 11 (35%) patients. The postoperative mortality rate was 10% (n=3). A total of 13 patients received additive chemotherapy (42%). The median time of follow up was 30 months (95% CI = 17- 43). The median OS was 39 months (95% CI: 34-44 months) with 1-month, 3-month, 1-, 3-, and 5-year survival estimates of 97%, 89%, 77%, 66%, and 41%. There was a significantly prolonged OS in patients who received additive chemotherapy compared to patients with only CRS+HITOC (median OS 69 <italic>vs</italic> 38 months; p= 0.048). The median RFS was 14 months (95% CI: 7-21 months). Conclusions: We observed that CRS+HITOC is a feasible approach with reasonable complications and prolonged survival as a part of multimodal concept for highly selected patients with secondary pleural metastases.